tiprankstipranks
Genmab A/S (GB:0MGB)
LSE:0MGB
UK Market
0MGB
Genmab A/S
RESEARCH TOOLSreports

Genmab A/S (0MGB) Share Forecast & Price Target

14 Followers
See the Price Targets and Ratings of:

0MGB Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Genmab
A/S
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0MGB Stock 12 Month Forecast

Average Price Target

kr1,823.87
▼(-2.91% Downside)
Based on 6 Wall Street analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is kr1,823.87 with a high forecast of kr2,800.00 and a low forecast of kr216.74. The average price target represents a -2.91% change from the last price of kr1,878.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"215":"kr215","1508":"kr1,508","2801":"kr2,801","861.5":"kr861.5","2154.5":"kr2,154.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr2.80K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1823.8651191066667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr1.82K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":216.74290424,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr216.74</span>\n  </div></div>","useHTML":true}}],"tickPositions":[215,861.5,1508,2154.5,2801],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1845.5,1918.923076923077,1992.3461538461538,2065.769230769231,2139.1923076923076,2212.6153846153848,2286.0384615384614,2359.4615384615386,2432.8846153846152,2506.3076923076924,2579.730769230769,2653.153846153846,2726.576923076923,{"y":2800,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1845.5,1843.8357783928204,1842.171556785641,1840.5073351784615,1838.8431135712822,1837.1788919641026,1835.514670356923,1833.8504487497437,1832.1862271425641,1830.5220055353846,1828.8577839282052,1827.1935623210256,1825.5293407138463,{"y":1823.8651191066667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1845.5,1720.2109926338462,1594.9219852676922,1469.6329779015384,1344.3439705353846,1219.0549631692306,1093.7659558030768,968.4769484369231,843.1879410707692,717.8989337046153,592.6099263384615,467.3209189723077,342.0319116061537,{"y":216.74290424,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1387.143,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1624.886,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1965.403,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1857.698,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2073.006,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2028.488,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2089.284,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1866.181,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1758.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1680.75,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1639,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1806.385,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1845.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Targetkr2,800Average Price Targetkr1,824Lowest Price Targetkr216.74
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on GB:0MGB
James Gordon CFA
Barclays
Barclays
kr2,500
Buy
33.08%
Upside
Reiterated
08/10/26
Barclays Keeps Their Buy Rating on Genmab A/S (0MGB)
UBS Analyst forecast on GB:0MGB
Xian Deng
UBS
UBS
kr2,700
Buy
43.73%
Upside
Reiterated
08/07/26
UBS Reaffirms Their Buy Rating on Genmab A/S (0MGB)
Morgan Stanley Analyst forecast on GB:0MGB
Judah Frommer
Morgan Stanley
Morgan Stanley
kr213.51→kr226.45
Hold
-87.95%
Downside
Reiterated
08/07/26
Morgan Stanley Reaffirms Their Hold Rating on Genmab A/S (0MGB)
Goldman Sachs Analyst forecast on GB:0MGB
Rajan Sharma
Goldman Sachs
Goldman Sachs
kr216.74
Buy
-88.46%
Downside
Reiterated
08/07/26
Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)
Jefferies Analyst forecast on GB:0MGB
Benjamin Jackson CFA
Jefferies
Jefferies
kr2,800
Buy
49.06%
Upside
Reiterated
07/08/26
Jefferies Keeps Their Buy Rating on Genmab A/S (0MGB)
Bank of America Securities Analyst forecast on GB:0MGB
Charlie Haywood
Bank of America Securities
Bank of America Securities
kr2,500
Buy
33.08%
Upside
Reiterated
06/30/26
Genmab: Buy Rating Reiterated on Strong Epkinly Phase III Data and Late-Stage Pipeline; Price Target Unchanged at DKK 2,500
Deutsche Bank Analyst forecast on GB:0MGB
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
kr2,400→kr2,250
Buy
19.78%
Upside
Reiterated
05/11/26
Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche BankGenmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank
Kepler Capital Analyst forecast on GB:0MGB
Jon Berggren
Kepler Capital
Kepler Capital
kr2,100
Hold
11.79%
Upside
Reiterated
05/07/26
Genmab A/S (0MGB) Gets a Hold from Kepler Capital
Exane BNP Paribas Analyst forecast on GB:0MGB
Victor Floc'h
Exane BNP Paribas
Exane BNP Paribas
kr2,400
Buy
27.76%
Upside
Upgraded
04/22/26
Genmab upgraded to Outperform from Neutral at BNP ParibasGenmab upgraded to Outperform from Neutral at BNP Paribas
Bernstein Analyst forecast on GB:0MGB
Justin Smith
Bernstein
Bernstein
kr1,015→kr1,400
Sell
-25.47%
Downside
Reiterated
02/23/26
Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks
J.P. Morgan Analyst forecast on GB:0MGB
Zain Ebrahim
J.P. Morgan
J.P. Morgan
kr1,650→kr2,050
Hold
9.13%
Upside
Reiterated
12/08/25
Genmab price target raised to DKK 2,050 from DKK 1,650 at JPMorganGenmab price target raised to DKK 2,050 from DKK 1,650 at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on GB:0MGB
James Gordon CFA
Barclays
Barclays
kr2,500
Buy
33.08%
Upside
Reiterated
08/10/26
Barclays Keeps Their Buy Rating on Genmab A/S (0MGB)
UBS Analyst forecast on GB:0MGB
Xian Deng
UBS
UBS
kr2,700
Buy
43.73%
Upside
Reiterated
08/07/26
UBS Reaffirms Their Buy Rating on Genmab A/S (0MGB)
Morgan Stanley Analyst forecast on GB:0MGB
Judah Frommer
Morgan Stanley
Morgan Stanley
kr213.51→kr226.45
Hold
-87.95%
Downside
Reiterated
08/07/26
Morgan Stanley Reaffirms Their Hold Rating on Genmab A/S (0MGB)
Goldman Sachs Analyst forecast on GB:0MGB
Rajan Sharma
Goldman Sachs
Goldman Sachs
kr216.74
Buy
-88.46%
Downside
Reiterated
08/07/26
Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)
Jefferies Analyst forecast on GB:0MGB
Benjamin Jackson CFA
Jefferies
Jefferies
kr2,800
Buy
49.06%
Upside
Reiterated
07/08/26
Jefferies Keeps Their Buy Rating on Genmab A/S (0MGB)
Bank of America Securities Analyst forecast on GB:0MGB
Charlie Haywood
Bank of America Securities
Bank of America Securities
kr2,500
Buy
33.08%
Upside
Reiterated
06/30/26
Genmab: Buy Rating Reiterated on Strong Epkinly Phase III Data and Late-Stage Pipeline; Price Target Unchanged at DKK 2,500
Deutsche Bank Analyst forecast on GB:0MGB
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
kr2,400→kr2,250
Buy
19.78%
Upside
Reiterated
05/11/26
Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche BankGenmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank
Kepler Capital Analyst forecast on GB:0MGB
Jon Berggren
Kepler Capital
Kepler Capital
kr2,100
Hold
11.79%
Upside
Reiterated
05/07/26
Genmab A/S (0MGB) Gets a Hold from Kepler Capital
Exane BNP Paribas Analyst forecast on GB:0MGB
Victor Floc'h
Exane BNP Paribas
Exane BNP Paribas
kr2,400
Buy
27.76%
Upside
Upgraded
04/22/26
Genmab upgraded to Outperform from Neutral at BNP ParibasGenmab upgraded to Outperform from Neutral at BNP Paribas
Bernstein Analyst forecast on GB:0MGB
Justin Smith
Bernstein
Bernstein
kr1,015→kr1,400
Sell
-25.47%
Downside
Reiterated
02/23/26
Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks
J.P. Morgan Analyst forecast on GB:0MGB
Zain Ebrahim
J.P. Morgan
J.P. Morgan
kr1,650→kr2,050
Hold
9.13%
Upside
Reiterated
12/08/25
Genmab price target raised to DKK 2,050 from DKK 1,650 at JPMorganGenmab price target raised to DKK 2,050 from DKK 1,650 at JPMorgan
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genmab A/S

3 Months
Emmanuel PapadakisDeutsche Bank
Success Rate
11/21 ratings generated profit
52%
Average Return
+4.90%
Copying Emmanuel Papadakis's trades and holding each position for 3 Months would result in 52.38% of your transactions generating a profit, with an average return of +4.90% per trade.
1 Year
Emmanuel PapadakisDeutsche Bank
Success Rate
13/21 ratings generated profit
62%
Average Return
+10.14%
Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +10.14% per trade.
2 Years
Emmanuel PapadakisDeutsche Bank
Success Rate
16/21 ratings generated profit
76%
Average Return
+17.81%
Copying Emmanuel Papadakis's trades and holding each position for 2 Years would result in 76.19% of your transactions generating a profit, with an average return of +17.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0MGB Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
1
0
0
0
Buy
6
8
8
9
7
Hold
1
1
1
1
1
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
10
9
10
8
In the current month, 0MGB has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0MGB average Analyst price target in the past 3 months is 1,823.87.
Each month's total comprises the sum of three months' worth of ratings.

0MGB Financial Forecast

0MGB Earnings Forecast

Next quarter’s earnings estimate for 0MGB is kr24.24 with a range of kr15.55 to kr38.88. The previous quarter’s EPS was kr31.81. 0MGB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 0MGB has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0MGB is kr24.24 with a range of kr15.55 to kr38.88. The previous quarter’s EPS was kr31.81. 0MGB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 0MGB has Performed in-line its overall industry.

0MGB Sales Forecast

Next quarter’s sales forecast for 0MGB is kr7.83B with a range of kr7.34B to kr9.47B. The previous quarter’s sales results were kr7.42B. 0MGB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 0MGB has Performed in-line its overall industry.
Next quarter’s sales forecast for 0MGB is kr7.83B with a range of kr7.34B to kr9.47B. The previous quarter’s sales results were kr7.42B. 0MGB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 0MGB has Performed in-line its overall industry.

0MGB Stock Forecast FAQ

What is GB:0MGB’s average 12-month price target, according to analysts?
Based on analyst ratings, Genmab A/S’s 12-month average price target is 1,823.87.
    What is GB:0MGB’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for GB:0MGB, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Genmab A/S a Buy, Sell or Hold?
        Genmab A/S has a consensus rating of Strong Buy, which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Genmab A/S’s share price target?
          The average share price target for Genmab A/S is 1,823.87. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is kr2,800.00 ,and the lowest forecast is kr216.74. The average share price target represents -2.91% Decrease from the current price of kr1,878.5.
            What do analysts say about Genmab A/S?
            Genmab A/S’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
              How can I buy shares of Genmab A/S?
              To buy shares of GB:0MGB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.